Samabriva and Affilogic entered into an Option and License Agreement to develop Nanofitin®-conjugated biotherapeutics to treat Lysosomal Storage Disorders

10 September 2018

Amiens, France, and Nantes, France, September 10, 2018 – Samabriva and Affilogic jointly announced that they recently entered into an Option and License Agreement to develop biotherapeutics for the treatment of patients with Lysosomal Storage Disorders. Within this Agreement, Samabriva will use Affilogic’s proprietary Nanofitins® technology to develop new therapies to address strong unmet needs in these patients such as the associated neurological damages.

In the framework of a research collaboration initiated in 2016, Samabriva will pursue the evaluation of Nanofitin® candidates selected by Affilogic from their proprietary libraries in combination with lysosomal enzymes. The partners will combine research efforts to optimize such Nanofitin®-conjugated biotherapeutics in order to satisfy unmet medical needs in the treatment of patients with Lysosomal Storage Disorders. Samabriva will have sole responsibility for their evaluation, preclinical and clinical developments.  Samabriva will be entitled to commercialize worldwide products incorporating Affilogic Nanofitins® resulting from the collaboration to treat Lysosomal Storage Disorders.

“Nearly 50 Lysosomal Storage Disorders are currently identified and, while clinical trials are in progress, there is currently no approved treatment for many of them” says Marina Guillet, Chief Executive Officer of Samabriva. “As we continue to advance the Nanofitin®-conjugated biotherapeutics through preclinical and clinical studies, we look forward to propose them as innovative treatments for patients with not addressed damages, such as the neurological disorders”.



“We are pleased to reinforce our collaboration with Samabriva, which broadens the scope of our ongoing partnered pre-clinical programs and enables us to generate additional data on Nanofitin®-conjugated biotherapeutics” continues Olivier Kitten, Chief Executive Officer of Affilogic. “This project directly promotes Affilogic’s strategy of Nanofitin®-Drug-Conjugates to enhance third-parties molecules, such as enzymes or antibodies”.


Under the terms of the Option and License agreement, Affilogic will receive an upfront payment and is eligible to receive further research funding, milestones payments and royalties by Samabriva. Further details of the agreement were not disclosed.

About Samabriva

Samabriva is a biotechnology company specialized in the development of recombinant proteins to treat the patients with rare diseases with a special focus on Lysosomal Storage Disorders. The company benefits from its access to innovative technologies to address these strongly unsatisfied unmet medical needs. Its lead drug candidate, SAM-01, is an original acid-sphingomyelinase recombinant enzyme for Niemann-Pick disease (« NPD »), with enhances features such as (a) a unique joint targeting of peripheral and neurological diseases and (b) extended half-life.

For more information, please visit

About Affilogic

Affilogic is a privately-owned biotech company specialized in discovery and development of Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

Nanofitins® are potent antibody-mimetics, exhibiting high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin is 20 times smaller than an antibody and hyperstable. Nanofitins are easily combined with each other by simple, rapid and proven methods to design an ideal targeted molecule.

Nanofitins® are mainly developed:

  • As Active Pharmaceutical Ingredient, for inhibition of inflammatory pathways or recruitment of immune cells,
  • As targeting probes for specific receptors in combination with a third-party molecule, for imaging application or Antibody-Drug-Conjugates-like strategy,
  • As enhancers for third-party molecules such as antibodies or enzymes.

Nanofitin®-based biotherapeutics and probes are currently being developed in collaboration with Sanofi, Takeda and several other undisclosed companies. Affilogic also runs early-stage programs especially exploring:

  • Non-injectable administration of Nanofitins®
  • Multifunctional Nanofitins® combinations

For more information, please visit